CHA Bio Group｜차바이오그룹

What CHA Bio Group｜차바이오그룹 does

CHA Bio Group (차바이오그룹) is a South Korea-based life sciences conglomerate founded in 2014 and headquartered in Bundang-gu, Seongnam-si. The group operates a vertically integrated "production-academic-research-hospital" (산·학·연·병) ecosystem spanning pharmaceutical development, cell and gene therapy (CGT) contract development and manufacturing, health functional foods, premium cosmetics, medical devices, and global healthcare services. Core CGT assets include Chabioteck (KOSDAQ: 085660) and Matica Biotechnology Inc., a US-based CGT CDMO subsidiary operating a cGMP facility in College Station, Texas with proprietary MatiMax™ HEK293/HEK293T cell lines, an AEX-HPLC AAV capsid separation analytical method, and the recently launched Matica Open Access Platform that retains customer IP and process ownership. Pharmaceutical operations center on CMG제약 (KOSDAQ: 058820), which developed the STARFILM® orally disintegrating film platform and secured FDA approval for Mezofy (aripiprazole oral film) — the first form-change improved generic drug from a Korean company to receive US FDA approval.

The group makes money through three primary revenue channels: (1) B2B CGT CDMO services via Matica Bio (US) and Matica Bio Labs (Korea), structured around milestone-based CMO contracts with biotech startups (Cirsium Biosciences, Asligen, Jungjin Bio Sciences, UCI Therapeutics, Ingenium Therapeutics) and academic/medical institutions; (2) global B2B2C healthcare services operating 96 medical institutions across 7 countries, including Hollywood Presbyterian Medical Center (434 beds, LA), City Fertility (21 IVF clinics across Australia), Singapore Medical Group (49 specialty clinics), and Total Cell Clinic Tokyo (regenerative medicine); and (3) B2C consumer health products including the 차바이오건강 health functional food brand (rebranded April 2026), EverCell premium anti-aging cosmetics, CHA&MOM skincare, and Pet Seven companion animal nutrition. CHA Bio Bank stores over 110,000 cord blood units, claimed to be Korea's largest.

The business model combines Korean clinical and R&D depth with US CGT manufacturing scale, supported by strategic capital partnerships — including a 10 billion KRW investment from LG CNS for digital healthcare platform development and a 2025 equity swap with Kakao (acquiring Kakao Healthcare while issuing a Chabioteck stake to Kakao). The group employs 14,000+ people globally, including 2,000+ researchers and 1,800+ medical staff. Distribution mixes direct enterprise sales (CDMO, hospitals), pharmacy/hospital channels (CMG제약 in Korea), and digital marketplaces (Naver Smart Store, Kakao, JD.com in China). The stated 2026 revenue target for CMG제약's China JD.com entry is 25 billion KRW, while CHA Healthcare (the global services arm) reported 6,485 billion KRW in 2022 (the larger group revenue across listed subsidiaries Chabioteck and CMG제약 is not separately disclosed but clearly exceeds this healthcare-only figure).

Name

CHA Bio Group｜차바이오그룹

Legal name

차바이오그룹 (CHA BIO GROUP)

Website

https://news.chabio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

CHA Bio Group is a South Korea-based life sciences conglomerate operating a production-academic-research-hospital ecosystem across CGT CDMO (Matica Bio), pharmaceuticals (Chabioteck, CMG Pharma), global healthcare services (Hollywood Presbyterian, City Fertility, Singapore Medical Group, TCC Tokyo), and consumer health/cosmetics brands, serving 7 countries and 96 medical institutions with 14,000+ employees.

Ownership category

akta.pro rank

Product category

Biotechnology and Healthcare Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Blood and Organ Banks (621991)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

akta.pro secondary industries

Biobank & Biospecimen Management LIMS (HLACAMAG), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ)

Keywords

• Cell and gene therapy CDMO
• Viral vector manufacturing
• Regenerative medicine services
• Biopharmaceutical development
• Stem cell banking

Headquarters

HQ city

성남시 분당구

HQ country

South Korea

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Go-to-market motion3 records

Distribution channels7 records

Marketing channels7 records

Core offering

CHA Bio Group (차바이오그룹) is a global life sciences conglomerate that operates an integrated bio ecosystem spanning cell and gene therapy (CGT) CDMO services (Matica Bio in Texas, USA and Matica Bio Labs in Korea), pharmaceutical manufacturing (CMG제약, KOSDAQ: 058820), health functional foods (차바이오건강), premium cosmetics (EVERCELL, CHA&MOM), pet nutrition (Pet Seven, IMC), and global healthcare services (Hollywood Presbyterian Medical Center, City Fertility, Singapore Medical Group, Total Cell Clinic Tokyo). The group leverages proprietary MatiMax™ cell lines, the Matica Open Access Platform, STARFILM® ODF technology, and Korea's largest cord blood biobank to serve biotech developers, healthcare providers, and end consumers across 7 countries.

Product overview

CHA Bio Group is a diversified biotechnology and healthcare conglomerate operating across pharmaceutical development, cell and gene therapy CDMO services, health functional foods, cosmetics, and global healthcare services. The group's core offerings include Matica Bio (US-based CGT CDMO with proprietary MatiMax™ cell lines and Open Access Platform), Matica Bio Labs (Korean CDMO), CMG제약 (pharmaceutical with STARFILM® ODF technology), and consumer brands like 차바이오건강 (health foods), 에버셀 (premium cosmetics), 차앤맘 (skincare), and Pet Seven (pet nutrition). The group also operates global healthcare facilities including Hollywood Presbyterian Hospital, City Fertility IVF clinics, Singapore Medical Group clinics, and Total Cell Clinic Tokyo. Key infrastructure includes CGB (Cell Gene Bioplatform) for integrated biotech cluster development and K-Bio CIC for startup support.

Differentiator

Problem solved

Functional benefit

Brands

• EVERCELL (에버셀): Premium anti-aging cosmetics brand operated by 차바이오에프앤씨 (CHA Bio F&C). Products include cell culture extracts, exosome-based formulations, and PDRN-containing beauty products.
• CMG건강연구소
• 차바이오건강
• Pet Seven (펫세븐)
• 차앤맘 (CHA&MOM)
• 오늘은 휴
• IMC (IngMedix Care)

Products and services

• Matica Bio CDMO Services (마티카 바이오테크놀로지) Viral vector and cell therapy CDMO services using proprietary MatiMax™ HEK293/HEK293T cell lines and cGMP manufacturing at a purpose-built facility in College Station, Texas, USA. Serves global biotech companies developing AAV-based gene therapies and cell therapies.
• Matica Bio Labs CDMO Services (마티카바이오랩스) Korean CGT CDMO services including MSC (mesenchymal stem cell) culture media production, CAR-NK cell therapy manufacturing, and contract manufacturing for regenerative medicine biotech companies. Serves domestic and international clinical-stage biotech firms.
• Matica Korea IIT Integrated Platform Solution (Matica K-IIT Program) Integrated platform combining Korean clinical execution with Matica Bio's US-based CGMP manufacturing, analytical development, and CMC expertise for investigator initiated trials (IIT) and early-stage clinical development of cell and gene therapies. Targets Korean clinical investigators and biotech companies seeking accelerated clinical data acquisition.
• Matica Open Access Platform Open, modular CDMO manufacturing framework offering transparent process and data access, guaranteed 100% client IP retention, avoiding long-term lock-in contracts, and providing flexible capacity for AAV and other viral vector production. Targets biotech developers seeking flexible, non-exclusive CDMO partnerships.
• MatiMax™ Cell Lines (HEK293/HEK293T) Proprietary HEK293 and HEK293T cell lines developed for viral vector production with approximately 17-hour cell division time (30% faster than industry standards), improved transfection efficiency, and higher viral vector productivity. Used in CDMO services and licensed for research and biomanufacturing applications.
• Mezofy (메조피) — Oral Film Aripiprazole Oral film formulation of aripiprazole for schizophrenia treatment, developed using CMG제약's STARFILM® ODF technology. First Korean form-change improved generic drug to receive FDA approval. Serves patients requiring schizophrenia treatment and the global generic drug market.
• STARFILM® ODF Technology Platform Proprietary orally disintegrating film (ODF) technology platform developed by CMG제약 that enables water-free medication intake in thin film form. Used as the foundation for Mezofy and applicable to other oral pharmaceuticals. Serves pharmaceutical companies seeking differentiated oral drug delivery formats.
• 차바이오건강 (CHA Bio Health) Health Functional Foods Health functional food brand offering slow-aging and beauty-from-within products (probiotics, psyllium husk, PDRN Active) under the rebrand from CMG건강연구소. Distributed via own e-commerce (chabiohealth.com), Naver Smartstore, Coupang, KakaoTalk channel, and JD.com (China). Serves Korean and Chinese health-conscious consumers.
• EVERCELL (에버셀) Premium Anti-Aging Cosmetics Premium anti-aging cosmetics brand operated by CHA Bio F&C, featuring the Cell Youth line with probiotic-derived exosomes, rose PDRN, cell culture extracts, and other bio-cosmetic ingredients. Targets consumers seeking premium skincare with bio-derived active ingredients.
• CHA&MOM (차앤맘) Family Skincare Family skincare brand under CMG제약 covering phytoceramide-based moisturizers, sunscreens, and pregnancy-safe skincare solutions for mothers and families. Serves expecting mothers and family-oriented consumers seeking safe, gentle skincare products.
• Pet Seven (펫세븐) Pet Nutrition Products Pet nutrition brand offering functional supplements for dogs and cats including joint health, kidney/urinary health, intestinal health, and immune function products. Manufactured at Korea's first HACCP-certified pet nutrition facility in Namyangju. Sold via Naver Smartstore and specialized pet stores.
• IMC Series (IngMedix Care) Premium Pet Nutrition Premium pet nutrition product line addressing cardiovascular, liver, joint, eye, intestinal, and immune health needs for dogs and cats. Manufactured at HACCP-certified Namyangju facility. Targets pet owners seeking premium, functionally targeted nutrition.
• Bio Bank (K-Cell Bank) Cord Blood & Stem Cell Banking Cord blood and stem cell banking service with capacity to store over 110,000 cord blood units, operated as part of the Bio Insurance (BI) business. Serves expecting parents seeking long-term biological insurance for their children and supporting future regenerative medicine applications.
• Hollywood Presbyterian Medical Center (할리우드 차병원) Services Full-service general hospital operating 434 beds in Los Angeles, USA, specializing in obstetrics and gynecology with 3,735 deliveries in 2022. Annual patient volume of approximately 14,000, 5,000+ surgeries. Serves diverse patient populations in the Los Angeles area, including Korean-American and medical tourism patients.
• City Fertility (호주 시티 퍼틸리티) IVF Services Australian fertility clinic network operating 21 IVF clinics across Brisbane, Sydney, Melbourne, and Perth. Performs 5,000+ IVF cycles annually, ranked among the world's top 3 fertility centers. IVF success rate improved 10%+ using CHA hospital protocols. Serves Australian patients seeking fertility treatment.
• Singapore Medical Group (SMG) Multi-Specialty Clinic Services Multi-specialty clinic group operating 49 clinics across Singapore, Indonesia, and Vietnam, covering women's health, oncology, imaging, pediatrics, and dermatology. Serves Southeast Asian patients across primary and specialty care.
• Total Cell Clinic Tokyo (TCC) Regenerative Medicine Services Regenerative medicine clinic in Tokyo providing stem cell and immune cell therapies for diabetes, chronic pain, and knee osteoarthritis. Treated over 10,000 patients since 2014. First foreign company to obtain Japanese regulatory approval for regenerative medicine (2015). Serves Japanese patients seeking regenerative therapies.
• Antiviral Hybrid Vaccine (VaxDome Partnership) Hybrid antiviral vaccine co-developed by Matica Bio and VaxDome targeting an antigen-agnostic non-invasive (nasal) vaccine approach. Targets broad viral protection independent of mutation variants, with influenza as the first disease model. Serves global public health preparedness for emerging viral threats.
• AAV Capsid Separation Analysis Method (AEX-HPLC) Proprietary analytical method using anion exchange high-performance liquid chromatography (AEX-HPLC) for distinguishing empty AAV capsids from full capsids, achieving 5x improved accuracy and 30-minute analysis completion versus existing methods. Supports ICH and FDA compliance for gene therapy manufacturing.

Quantifiable outcome

• 세포분열 시간 마티맥스 기준 약 17시간(업계 평균 대비 30% 빠름)
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Cirsium BiosciencescoreTechnology or Integration · 17 June 2026마티카 바이오테크놀로지와 Cirsium Biosciences가 마티카 오픈 액세스 플랫폼을 통한 AAV 제조 협력. Cirsium의 식물 기반 AAV 배양(업스트림) 기술과 마티카 바이오의 정제(다운스트림) 및 분석 역량을 결합하여 유전자치료제 생산 비용과 공정 복잡성 문제를 동시에 해결하는 것을 목표로 함.
• 서지엄 바이오사이언스(Cirsium Biosciences)coreTechnology or Integration · 1 June 2026마티카 바이오테크놀로지가 마티카 오픈 액세스 플랫폼을 공식 런칭하고 첫 번째 고객사로 Cirsium Biosciences와 AAV 기반 차세대 유전자치료제 개발 협력 계약 체결. 2025년 AAV 벡터 CDMO 계약에서 확장.
• 한국 top 임상 및 병원 네트워크coreStrategic or Co-development Partner · 1 June 2026마티카 바이오가 Accelerated Matica Korea IIT Integrated Platform Solution 출시. 한국의 top 임상 실행 및 병원 네트워크와 협력하여 IIT(연구자주도 임상시험) 및 초기 전임상 개발 프로그램 지원.
• 유씨아이테라퓨틱스(UCI Therapeutics)coreStrategic or Co-development Partner · 1 March 2026마티카바이오랩스가 유씨아이테라퓨틱스와 CAR-NK 치료제 'UCI-101' 위탁생산 및 품질시험 계약 체결.
• 인게니움테라퓨틱스(Ingenium Therapeutics)coreStrategic or Co-development Partner · 1 January 2026마티카바이오랩스와 인게니움테라퓨틱스 간 첨단재생의료 치료제 CMO 계약. 자가유래 Memory NK세포치료제 생산 및 품질시험 수행.
• 아스리젠(Asligen)coreStrategic or Co-development Partner · 15 June 2025마티카바이오랩스와 아스리젠이 와튼젤리 유래 중간엽줄기세포(WJ-MSC) 제조 CDMO 계약 체결. 아스리젠 개발 중인 관절 연골재생 치료제 연구에 활용.
• 정진바이오사이언스minorStrategic or Co-development Partner · 1 January 2025마티카바이오랩스가 정진바이오사이언스와 중간엽줄기세포 배양액 위·수탁생산(CMO) 계약 체결. 고품질 줄기세포 배양액을 생산하여 정진바이오사이언스에 공급.
• 연세대학교 바이오헬스기술지주회사coreStrategic or Co-development Partner차바이오텍과 연세대학교 바이오헬스기술지주회사가 K-Bio CIC 기반 글로벌 바이오헬스 스타트업 육성을 위한 MOU 체결. 유망 바이오 기업 초기 발굴 및 초기 R&D부터 임상·생산·글로벌 진출 연계 협력.
• 한국노바티스coreStrategic or Co-development Partner차바이오텍과 한국노바티스가 K-Bio CIC 오픈이노베이션센터 구축 협력 MOU 체결. CGB 기반 바이오 스타트업 혁신기술 발굴 및 사업화, 글로벌 시장 진출 지원 협력.
• 써모 피셔 사이언티픽(Thermo Fisher Scientific)coreTechnology or Integration차바이오텍과 써모 피셔 사이언티픽 MOU 체결. K-Bio CIC에 글로벌 바이오 연구 인프라 구축 협력.
• LG CNScoreTechnology or Integration차바이오텍이 LG CNS로부터 100억 원 규모 투자 유치 및 AX·DX 사업 협력 MOU 체결. 디지털 헬스케어 서비스와 플랫폼 구축 위한 전략적 협력.
• 한화손해보험·한화생명minorStrategic or Co-development Partner차바이오그룹(차바이오텍·차헬스케어·차AI헬스케어)과 한화손해보험·한화생명이 바이오, AI·데이터 기반 디지털 헬스케어, 금융 분야 협력을 위한 MOU 체결.
• 카카오(카카오헬스케어)coreStrategic or Co-development Partner차바이오그룹이 카카오와 지분 교환으로 디지털 헬스케어 전략적 협력 강화. 카카오헬스케어 지분 취득, 카카오에 차바이오텍 지분 제공.
• 백스돔(VaxDome)coreStrategic or Co-development Partner마티카 바이오가 미국 생명공학기업 백스돔(VaxDome)과 항바이러스 하이브리드 백신 공동 개발. 백스돔은 돌연변이 유형에 관계없이接种 가능한 비침습 백신 개발에 주력.
• 홈앤코스메디칼coreChannel Partner/ Reseller/ DistributorCMG제약과 홈앤코스메디칼 협력하여 중국 JD.com 입점. CMG제약이 건강기능식품과 반려동물 영양제 공급, 홈앤코스메디칼이 현지 소비자 마케팅 및 제품 공급 관리 담당.
• 릿지어아시아minorStrategic or Co-development Partner마티카바이오랩스와 인수^jasijasi MOU 체결.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Catalent: Global CDMO with established viral vector and cell therapy manufacturing services. Comparable as a major CGT CDMO incumbent offering both plasmid DNA and viral vector production at commercial scale across multiple modalities.
• Lonza Group: Global CDMO leader with extensive viral vector and cell therapy capabilities. Comparable as the dominant incumbent in the CGT CDMO space where Matica Bio competes, offering significantly larger bioreactor scale and broader service portfolio.
• WuXi AppTec / WuXi Biologics: Chinese-headquartered global CDMO with biologics and CGT capabilities. Comparable as a large-scale Asian CDMO competitor with broader service offering and stronger China market access than CHA Bio Group.
• Thermo Fisher Scientific (CDMO services): Global life sciences tools and CDMO services leader with viral vector manufacturing through Patheon/Brammer Bio. Comparable as a broad incumbent offering CGT manufacturing services alongside extensive analytical and process development capabilities.

Direct peers

• Celltrion: Korean biopharmaceutical company developing biosimilars and biologics. Comparable as a major Korean biotech peer with similar KOSDAQ listing status and focus on contract manufacturing and global market expansion.
• Samsung Biologics: Korean CDMO leader providing biopharmaceutical manufacturing services. Comparable as a Korean-listed CDMO peer competing for global biopharma contracts, though Samsung Biologics focuses on monoclonal antibodies and biologics rather than viral vector CGT.
• AGC Biologics: Global CDMO specializing in cell therapy, viral vectors, and biologics manufacturing. Comparable as a mid-tier CGT CDMO peer with similar viral vector production focus and customer base of biotech developers.
• SK Bioscience: Korean vaccine and biopharmaceutical developer with manufacturing capabilities. Comparable as a Korean-listed biotech peer expanding into global vaccine and CGT manufacturing partnerships.
• Rentschler Biopharma: European family-owned CDMO focused on viral vectors and complex biologics. Comparable as a mid-sized CDMO peer specializing in viral vector production for gene therapy developers with similar client profile to Matica Bio.

Emerging players

• Charles River Laboratories: CRO/CDMO with viral vector manufacturing capabilities (acquired Cobra Biologics). Comparable as an integrated drug discovery and CGT manufacturing peer serving similar biotech developer clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cha-bio-group

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CHA Bio Group｜차바이오그룹